Global Crohn’s Disease Drug Forecast and Market Analysis to 2029 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Crohn’s Disease – Global Drug Forecast and Market Analysis to 2029” report has been added to ResearchAndMarkets.com’s offering.

Global sales in the CD market are expected to grow to $12.6B by 2029, at a Compound Annual Growth Rate (CAGR) of 5.5% from 2019-2029. The publisher forecasts the US CD market to grow to $10.4B (82.3% of global sales), the 5EU to grow to $1.9B (14.7% of global sales), Japan to grow to $174.9M (1.4% of global sales), and Canada to grow to $200.1M (1.6% of global sales) over the next 10 years.

Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is composed of two chronic autoimmune diseases that cause intestinal inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area; however, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission. The CD market has historically been reliant on anti-tumor necrosis factor (anti-TNF) therapies that have been available for over a decade but recent developments have led to research on novel treatment mechanisms. (Read more…)

In May 2014, Takeda gained approval for Entyvio (vedolizumab), the first-in-class ?4?7 integrin inhibitor that was the first new biologic treatment approved for CD that was not an anti-TNF, and this was followed by Janssen’s Stelara (ustekinumab) in September 2016, which was a first-in-class interleukin (IL)-12 and 23 inhibitor. Moreover, biosimilars of currently marketed anti-TNF biologics recently entered the market, with Remicade (infliximab) biosimilars first marketed in 2015 in Europe and 2016 in the US, and adalimumab biosimilars first marketed in Europe in 2018.

This is likely to result in a highly competitive market for patients who have failed first-line agents, such as steroids, aminosalicylates, and immunomodulators. Competition will intensify with the arrival of new anti-IL-23 treatments and new classes of therapies in development, Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor (S1PR) modulators, which will offer a more convenient form of administration. With existing unmet need for all patients, particularly CD patients that experience loss of response to biologic treatment and patients that develop fistulizing disease, CD represents an important immunology sector for drug developers.

Companies Mentioned

• Janssen
• AbbVie
• Takeda
• UCB
• Genentech
• Eli Lilly
• AstraZeneca
• BMS
• Galapagos
• Arena Pharmaceuticals
• RedHill Biopharma

Key Questions Answered

• Over the forecast period, the CD market will see the entry of pipeline agents such as anti-IL-23 biologics, JAK inhibitors, and S1P receptor modulators, the sales of which will offset the loss of sales caused by the entry of biosimilars. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?
• Key Opinion Leaders (KOLs) interviewed by the publisher have indicated that there are several unmet needs within the CD indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
• The CD market is likely to become a turbulent space throughout the forecast period and beyond. Which companies are set to be major players in CD during the forecast period?

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global CD therapeutics market from 2019-2029.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Crohn’s Disease: Executive Summary

2.1 Crohn’s Disease Market to Experience Sizable Growth from 2019?2029

2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves

2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period

2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Crohn’s Disease Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.5 Epidemiological Forecast for CD (2019-2029)

5.6 Discussion

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

6.5 Canada

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Improved Drug Efficacy and Safety in the Maintenance Setting

8.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis

8.4 Improved Medical Management of Perianal Fistulas

8.5 Patient Adherence to Maintenance Therapy

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

11 Market Outlook

12 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/xjgdh9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900